Phase 4 N=109 Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients
Surgical Conditions
Primary: Surgical Rating — 4.2; 4.8 units on a scale — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Minocycline for Bipolar Depression
Bipolar Depression
Primary: Change in Scores on the Montgomery-Asberg Depression Rating Scale (MADRS) — -14.6 units on a scale
Phase 4 N=106 Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins
Varicose Veins
Primary: Efficacy in Treating Reticular Veins by Photographs: Mean Percent Reticular Vein Disappearance Two Months After Treatment. — 95.17; 85.40 % of Reticular Veins that…
Phase 4 N=126 Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation
Sedation
Primary: Number of Participants With Sub-clinical Respiratory Depression and Clinical Events Associated With Respiratory Depression During the Sedation Procedure — 11; 12…
Phase 4 N=64 Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients
Alcohol Dependence
Primary: Percent Abstinent Days — 40; 36 percentage of abstinent days
Phase 4 N=36 A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion
Anesthesia
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Fospropofol (AUC(0-inf)) — 16522; 25052; 36629 ug.h/L
Phase 4 N=117 Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
Type 2 Diabetes
Primary: Change in 24-hour Mean Weighted Glucose — 185.7; 183.8; 158.3; 176.9 (mg/dL) — p=<0.001
Phase 4 N=2,354 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
COPD · COPD Exacerbation · Lung Diseases
Primary: Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year. — 1.27; 1.17 COPD exacerbations per patient per year — p=0.1634
Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
Phase 4 N=532 Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 — -1.61; -1.58 Percentage of HbA1c
Phase 4 N=53 Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13 — -18.5; -9.7 mg/dL — p=0.245
Phase 4 N=40 Ulcer Prevention Study in Post Gastric Bypass Patients
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
Phase 4 N=134 A Study Comparing CoQ10 Levels While Taking 3 Different Statins
Hypercholesterolemia
Primary: Changes in Plasma CoQ10 Levels — -96.70; -110.42; -103.91; -721.09 μg/g
Phase 4 N=14 Ranolazine for the Treatment of Chest Pain in HCM Patients
Hypertrophic Cardiomyopathy
Primary: QT Interval — 462.8 msec
Phase 4 N=127 Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)
Blood Loss
Primary: The Change in Hemoglobin (Hb) From the Day of Surgery — 2.6; 3.2; 2.6; 3.7 g/dl